Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides that potentiate receptor function in vivo

被引:168
作者
Lindsley, CW [1 ]
Wisnoski, DD
Leister, WH
O'Brien, JA
Lemaire, W
Williams, DL
Burno, M
Sur, C
Kinney, GG
Pettibone, DJ
Tiller, PR
Smith, S
Duggan, M
Hartman, GD
Conn, PJ
Huff, JR
机构
[1] Merck Res Labs, Dept Med Chem, Technol Enabled Synth, W Point, PA 19486 USA
[2] Merck Res Labs, Dept Neurosci, W Point, PA 19486 USA
[3] Merck Res Labs, Dept Drug Metab, W Point, PA 19486 USA
关键词
D O I
10.1021/jm049400d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This report describes the discovery of the first centrally active allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). Appropriately substituted N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides (e.g., 8) have been identified as a novel class of potent positive allosteric modulators of mGluR5 that potentiate the response to glutamate. An iterative analogue library synthesis approach provided potentiators with excellent potency and selectivity for mGluR5 (vs mGluRs 1-4, 7, 8). Compound 8q demonstrated in vivo proof of concept in an animal behavior model where known antipsychotics are active, supporting the development of new antipsychotics based on the NMDA hypofunction model for schizophrenia.
引用
收藏
页码:5825 / 5828
页数:4
相关论文
共 23 条
[1]  
ALAGARSAMY S, 2001, CURR OPIN NEUROBIOL, V3, P114
[2]   COMPETITIVE NMDA RECEPTOR ANTAGONISTS ATTENUATE THE BEHAVIORAL AND NEUROCHEMICAL EFFECTS OF AMPHETAMINE IN MICE [J].
BRISTOW, LJ ;
THORN, L ;
TRICKLEBANK, MD ;
HUTSON, PH .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1994, 264 (03) :353-359
[3]   Regulation of neurotransmitter release by metabotropic glutamate receptors [J].
Cartmell, J ;
Schoepp, DD .
JOURNAL OF NEUROCHEMISTRY, 2000, 75 (03) :889-907
[4]   Metabotropic Glutamate Receptors: Potential Drug Targets for the Treatment of Schizophrenia [J].
Chavez-Noriega, Laura E. ;
Schaffhauser, Herve ;
Campbell, Una C. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (03) :261-281
[5]   Pharmacology and functions of metabotropic glutamate receptors [J].
Conn, PJ ;
Pin, JP .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1997, 37 :205-237
[6]   Allosteric modulators of group I metabotropic glutamate receptors: novel subtype-selective ligands and therapeutic perspectives [J].
Gasparini, F ;
Kuhn, R ;
Pin, JP .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (01) :43-49
[7]   2-methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist [J].
Gasparini, F ;
Lingenhöhl, K ;
Stoehr, N ;
Flor, PJ ;
Heinrich, M ;
Vranesic, I ;
Biollaz, M ;
Allgeier, H ;
Heckendorn, R ;
Urwyler, S ;
Varney, MA ;
Johnson, EC ;
Hess, SD ;
Rao, SP ;
Sacaan, AI ;
Santori, EM ;
Veliçelebi, G ;
Kuhn, R .
NEUROPHARMACOLOGY, 1999, 38 (10) :1493-1503
[8]   Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review [J].
Geyer, MA ;
Krebs-Thomson, K ;
Braff, DL ;
Swerdlow, NR .
PSYCHOPHARMACOLOGY, 2001, 156 (2-3) :117-154
[9]   Evaluation of drug interactions with P-glycoprotein in drug discovery:: In vitro assessment of the potential for drug-drug interactions with P-glycoprotein [J].
Hochman, JH ;
Yamazaki, M ;
Ohe, T ;
Lin, JH .
CURRENT DRUG METABOLISM, 2002, 3 (03) :257-273
[10]   Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor:: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethyl-amine [J].
Johnson, MP ;
Baez, M ;
Jagdmann, GE ;
Britton, TC ;
Large, TH ;
Callagaro, DO ;
Tizzano, JP ;
Monn, JA ;
Schoepp, DD .
JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (15) :3189-3192